Product news from the 10/03/06 News Brief

Share this article:
The FDA granted expanded indication to GlaxoSmithKline’s anti-seizure medicine Lamictal (lamotrigine) for treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, also known as "grand mal" seizures, in children aged 2 and older and adults. Axcan Pharma said the FDA has issued an approval letter for the company's New Drug Application for Pylera (formerly Helizide). Pylera is a patented 3-in-1 capsule triple therapy, for the eradication of Helicobacter pylori, a bacterium recognized as being the main cause of gastric and duodenal ulcers. Gilead Sciences has agreed to acquire Myogen in a deal worth approximately $2.5 billion. The deal means that Gilead will acquire Myogen's main drug candidate, Ambrisentan, a pulmonary arterial hypertension treatment in late-stage clinical trials.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions